MARKET

KALV

KALV

Kalvista
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.27
+0.11
+0.52%
Closed 16:00 07/23 EDT
OPEN
22.12
PREV CLOSE
21.16
HIGH
22.12
LOW
20.79
VOLUME
239.57K
TURNOVER
--
52 WEEK HIGH
45.00
52 WEEK LOW
9.62
MARKET CAP
519.76M
P/E (TTM)
-8.8349
1D
5D
1M
3M
1Y
5Y
Hedge Funds Are Crazy About KalVista Pharmaceuticals, Inc. (KALV)
In this article we will take a look at whether hedge funds think KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend mi...
Insider Monkey · 6d ago
KalVista Pharmaceticals EPS misses by $0.10
KalVista Pharmaceticals (KALV): Q4 GAAP EPS of -$0.65 misses by $0.10.Cash, cash equivalents and marketable securities were $248.9M as of April 30, 2021, compared to $67.7M as of April 30,
Seekingalpha · 07/13 10:42
KalVista Pharmaceuticals Q4 EPS $(0.65) Down From $(0.37) YoY
KalVista Pharmaceuticals (NASDAQ:KALV) reported quarterly losses of $(0.65) per share. This is a 75.68 percent decrease over losses of $(0.37) per share from the same period last year.
Benzinga · 07/13 10:32
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
--- FDA Response Submission for KVD824 Phase 2 Clinical Hold Expected Q3 2021 -
Business Wire · 07/13 10:30
KalVista Pharmaceuticals Q1 Adjusted Loss Widens, Revenue Falls
MT Newswires · 07/13 07:30
KalVista Pharma's KVD900 slows progression, accelerates resolution of attacks in HAE patients
KalVista Pharmaceuticals (KALV) presents data for its oral drug candidates at the European Academy of Allergy and Clinical Immunology ((EAACI)) Congress.Data presentations include Phase 2 data for KVD900 for oral
Seekingalpha · 07/12 12:15
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data presented for
Benzinga · 07/12 11:36
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.
Benzinga · 07/11 20:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KALV. Analyze the recent business situations of Kalvista through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KALV stock price target is 54.71 with a high estimate of 61.00 and a low estimate of 48.00.
EPS
Institutional Holdings
Institutions: 154
Institutional Holdings: 25.43M
% Owned: 104.05%
Shares Outstanding: 24.44M
TypeInstitutionsShares
Increased
43
5.78M
New
53
6.76M
Decreased
17
1.80M
Sold Out
18
3.54M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.89%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Martin Edwards
Chief Executive Officer/Director
Thomas Crockett
Chief Financial Officer
Benjamin Palleiko
Senior Vice President
Andreas Maetzel
Senior Vice President
Michael Smith
Chief Scientific Officer
Edward Feener
Other
Christopher Yea
Independent Director
Albert Cha
Independent Director
Brian Pereira
Independent Director
Daniel Soland
Independent Director
Nancy Stuart
Independent Director
Edward Unkart
No Data
About KALV
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Webull offers kinds of Kalvista Pharmaceuticals Inc stock information, including NASDAQ:KALV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KALV stock methods without spending real money on the virtual paper trading platform.